Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review

Hepatology Research

Volumn 42, Issue 12, 2012, Pages 1248-1251

  Omazzi, Barbara ^a   Prada, Alberto ^a   Borroni, Gianmario ^b   Sacrini, Francesco ^c  

^a RHO HOSPITAL   (Italy)

^b ASL Provincia di Milano 1   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Hepatitis C; Irreversible alopecia universalis; Side effects; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; CITALOPRAM; CORTICOSTEROID; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PSORALEN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ALOPECIA UNIVERSALIS; ARTICLE; CASE REPORT; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; FEVER; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUVA; RELAPSE; TREATMENT DURATION; VIRUS LOAD;

EID: 84870260390     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01036.x     Document Type: Article

References (21)

1. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351: 351-5.
2. Ghany MG, Strader DB, Thomas DL etal. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-73.
3. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
4. Taliani G, Biliotti E, Capanni M etal. Alopecia universalis following interferon alfa-2b and ribavirin treatment for hepatitis C. J Chemother 2005; 17: 212-14.
5. Kartal ED, Alpat SN, Ozgunes I etal. Reversible alopecia universalis secondary to PEG-interferon α-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007; 19: 817-20.
6. Demirturk N, Aykin N, Demirdal T etal. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Eur J Dermatol 2006; 16: 579-94.
7. Midian-Singh R, Alagugurusamy S, Agrawal R. Alopecia universalis following interferon Alfa-2b and ribavirin treatment for hepatitis C. Gastroenterol Hepatol 2007; 3: 644-5.
8. Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol 2009; 23: 677-583.
9. Fleming CJ, MacKie RM. Alpha interferon induced hair discolouration. Br J Dermatol 1996; 135: 337-8.
10. Misery L. Diffuse hypertrichosis in the course of hepatitis C treatment by IFN-alpha and ribavirin. J Interferon Cytokine Res 2002; 22: 881-2.
11. Tosti A, Miscali C, Baldazzi F etal. Telogen effluvium due to recombinant interferon alfa-2b. Dermatology 1992; 184: 124-5.
12. Agesta N, Zabala R, Diaz-Perez JL. Alopecia areata during interferon alfa-2b/ ribavirin therapy. Dermatology 2002; 205: 300-1.
13. Elder DE, Elenitsas R, Johnson BL Jr etal. Alopecia areata. In: Elder DE, Elenitsas R, Johnson B, Murphy G, ed. Lever's Histopathology of the Skin, 9th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2005; 483-5.
14. Tosti A, La Placa M, Placucci F etal. No correlation between CMV and alopecia areata. J Invest Dermatol 1996; 107: 443.
15. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-19.
16. Alexis AF, Dudda-Subramanya R, Sinha AA. Alopecia Areata: autoimmune basis of hair loss. Eur J Dermatol 2004; 14: 364-70.
17. Fisher AA. Immediate and delayed allergic contact reactions to polyethylene glycol. Contact Dermatitis 1978; 4: 135-8.
18. Ruiz-Doblado S, Carrizosa A, Garcia Hernandez MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol 2003; 42: 434-7.
19. Hedenmalm K, Sundstrom A, Spigset O. Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs). Pharmacoepidemiol Drug Saf 2006; 15: 719-25.
20. Alzolibani AA. Epidemiologic and genetic characteristics of alopecia areata (part 1). Acta Dermatoven APA 2011; 20: 191-8.
21. Shafa S, Borum ML, Iglehon E. A case of irreversible alopecia associated with ribavirin and peg-interferon therapy. Eur J Gastroenterol Hepatol 2010; 22: 122-3.